JP2024538706A5 - - Google Patents

Info

Publication number
JP2024538706A5
JP2024538706A5 JP2024520924A JP2024520924A JP2024538706A5 JP 2024538706 A5 JP2024538706 A5 JP 2024538706A5 JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024520924 A JP2024520924 A JP 2024520924A JP 2024538706 A5 JP2024538706 A5 JP 2024538706A5
Authority
JP
Japan
Prior art keywords
seq
monomer
construct
terminus
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077690 external-priority patent/WO2023060188A1/en
Publication of JP2024538706A publication Critical patent/JP2024538706A/ja
Publication of JP2024538706A5 publication Critical patent/JP2024538706A5/ja
Pending legal-status Critical Current

Links

JP2024520924A 2021-10-08 2022-10-06 活性化可能サイトカイン構成体及び併用方法 Pending JP2024538706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163253893P 2021-10-08 2021-10-08
US63/253,893 2021-10-08
US202263328525P 2022-04-07 2022-04-07
US63/328,525 2022-04-07
PCT/US2022/077690 WO2023060188A1 (en) 2021-10-08 2022-10-06 Activatable cytokine constructs and combination methods

Publications (2)

Publication Number Publication Date
JP2024538706A JP2024538706A (ja) 2024-10-23
JP2024538706A5 true JP2024538706A5 (cg-RX-API-DMAC7.html) 2025-10-10

Family

ID=84272320

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520924A Pending JP2024538706A (ja) 2021-10-08 2022-10-06 活性化可能サイトカイン構成体及び併用方法

Country Status (10)

Country Link
US (2) US20230192798A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412635A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538706A (cg-RX-API-DMAC7.html)
KR (1) KR20240099172A (cg-RX-API-DMAC7.html)
AU (1) AU2022360371B2 (cg-RX-API-DMAC7.html)
CA (1) CA3233707A1 (cg-RX-API-DMAC7.html)
IL (1) IL311972A (cg-RX-API-DMAC7.html)
MX (1) MX2024004301A (cg-RX-API-DMAC7.html)
TW (1) TW202334185A (cg-RX-API-DMAC7.html)
WO (1) WO2023060188A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024353718A1 (en) * 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
WO2025195305A1 (en) * 2024-03-16 2025-09-25 Vibrant Pharma Limited Multispecific antigen binding proteins and uses thereof
CN120932734B (zh) * 2025-10-13 2026-01-30 良渚实验室 利用中介序列msa与扩散掩码机制的肽序列生成模型及生成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
US8399219B2 (en) 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
US9487590B2 (en) 2012-09-25 2016-11-08 Cytomx Therapeutics, Inc. Activatable antibodies that bind interleukin-6 receptor and methods of use thereof
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
PT3215528T (pt) 2014-11-06 2019-10-11 Hoffmann La Roche Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
JP2020528878A (ja) * 2017-06-20 2020-10-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム がん治療用インターフェロンプロドラッグ
JP2022512124A (ja) 2018-12-06 2022-02-02 シートムエックス セラピューティクス,インコーポレイテッド マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法
BR112022009110A2 (pt) * 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
KR20230157448A (ko) * 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법

Similar Documents

Publication Publication Date Title
Ashkenazi et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
US12152060B2 (en) Interleukin-2 variants and methods of uses thereof
JP7682150B2 (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP2024153643A5 (cg-RX-API-DMAC7.html)
US20220235109A1 (en) Novel interleukin-2 variants for the treatment of cancer
CN103172746B (zh) 三聚体Fc融合蛋白及其用途
AU2002324625B2 (en) Interleukin-1 receptors in the treatment of diseases
RU2011138951A (ru) Пропротеины и способы их применения
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
EA011992B1 (ru) Гибридный белок антитела l19 к фибронектину ed-b и интерлейкина 12
JP2003530070A (ja) Fc融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出
JP2025169347A (ja) Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体
KR20030048041A (ko) 표적-특이적 프로드럭으로서 사용하기 위한항체-사이토카인-사이토카인 억제제로 이루어진 융합단백질(셀렉토카인)
JP2024517871A (ja) プロテアーゼ活性化治療剤を含む組成物および方法
RU2007119989A (ru) Композиции, слитые конструкции и конъюгаты plad домена
JP2024511387A5 (cg-RX-API-DMAC7.html)
JP2018537093A5 (cg-RX-API-DMAC7.html)
KR20210084473A (ko) 항인간 Fn14 항체
JP2024534062A (ja) 誘導性サイトカインプロドラッグ及びpd-1/pd-l1併用療法
JP2024528660A (ja) リンカーポリペプチド
NZ501831A (en) Trail binding protein (TRAIL-BP) showing significant homology to the extracellular domains of members of the tumour necrosis factor receptor (TNF-R) and is anchored to cell surface via glycosylphosphatidylinositol (GPI) linkage
CN116113428A (zh) 白细胞介素-2突变蛋白及其用途
CA2952902A1 (en) Anti-il4-il 13 bispecific antibodies
RU2007117716A (ru) Химерный белок
JP2011507498A5 (cg-RX-API-DMAC7.html)